HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.
| Data(s) |
2002
|
|---|---|
| Resumo |
BACKGROUND: HER-2/neu status was determined by immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) methods in more than 300 paraffin-embedded primary breast cancer samples. MATERIALS AND METHODS: HER-2/neu status was determined by FISH using the PathVysion kit (Vysis) and by IHC using either a monoclonal antibody CB11 or a cocktail of antibodies: the monoclonal TAB250 and the polyclonal pAb1. RESULTS: Of the 324 cases evaluable by IHC, 65 out of 318 (20%) and 24 out of 324 (7%) were scored as positive when using the antibody cocktail and the CB11, respectively. HER-2/neu gene amplification occured in 64 out of 324 cases (20%). Concordance of FISH and IHC was found in 285 out of 318 cases (90%) and 278 out of 324 cases (86%) using the cocktail and the CB11, respectively. CONCLUSION: The cost-effectiveness analysis revealed that the use of a sensitive IHC method followed by confirmation of positive results by FISH considerably decreased the FISH costs and may become standard practice for HER-2/neu evaluation. Comparative Study Journal Article Multicenter Study Research Support, Non-U.S. Gov't info:eu-repo/semantics/published |
| Formato |
No full-text files |
| Identificador |
uri/info:pmid/12174949 local/VX-005565 http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/55347 |
| Idioma(s) |
en |
| Fonte |
Anticancer research, 22 (4 |
| Palavras-Chave | #Sciences bio-médicales et agricoles #Antibodies, Monoclonal #Breast Neoplasms -- genetics #Breast Neoplasms -- pathology #Female #Humans #Immunohistochemistry #In Situ Hybridization, Fluorescence #Laboratories -- standards #Receptor, erbB-2 -- analysis #Receptor, erbB-2 -- genetics #Reproducibility of Results |
| Tipo |
info:eu-repo/semantics/article info:ulb-repo/semantics/articlePeerReview info:ulb-repo/semantics/openurl/article |
